Page 142 - Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis

Chapter 6
20. Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, Barelli P, Kim D, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017;58(9):1442-9.
21. Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, et al. (177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017;7(7):1928-39.
22. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273-82.
23. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2013;40(5):800-16.
24. Lau J, Jacobson O, Niu G, Lin KS, Benard F, Chen X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjug Chem. 2019;30(3):487-502.
25. Rousseau E, Lau J, Zhang Z, Uribe CF, Kuo HT, Zhang C, et al. Effects of adding an albumin binder chain on [(177)Lu]Lu-DOTATATE. Nucl Med Biol. 2018;66:10-7.
26. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51(7):1049-58.
27. Farkas R, Siwowska K, Ametamey SM, Schibli R, van der Meulen NP, Muller C. (64)Cu- and (68) Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate. Mol Pharm. 2016;13(6):1979-87.
28. Benesova M, Umbricht CA, Schibli R, Muller C. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018;15(3):934-46.
29. Umbricht CA, Benesova M, Schibli R, Muller C. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol Pharm. 2018;15(6):2297-306.
30. Verhoeven, Seimbille, Dalm. Therapeutic Applications of Pretargeting. Pharmaceutics. 2019;11(9):434.
31. Stéen EJL, Edem PE, Nørregaard K, Jørgensen JT, Shalgunov V, Kjaer A, et al. Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. Biomaterials. 2018;179:209-45.
32. Dalm SU, Haeck J, Doeswijk GN, De Blois E, De Jong M, Van Deurzen C. SSTR-mediated Breast Cancer Imaging: Is There A Role For Radiolabeled SSTR Antagonists? Journal of Nuclear Medicine. 2017:jnumed.116.18903.
33. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103(44):16436-41.
34. de Blois E, Chan HS, de Zanger R, Konijnenberg M, Breeman WA. Application of single-vial ready- for-use formulation of 111In- or 177Lu-labelled somatostatin analogs. Appl Radiat Isot. 2014;85:28- 33.
35. Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, et al. [111In-DTPA-D-Phe1]- octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49(22):1583-91.
36. Breeman WAP dBE, Krenning E. Effects of quenchers on the radiochemical purity of 111 In-labeled peptides. J Nucl Med. 2007;48.
37. Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, et al. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. J Nucl Med. 2016;57(2):260-5.
38. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.
39. Melis M, Bijster M, de Visser M, Konijnenberg MW, de Swart J, Rolleman EJ, et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumors. European journal of nuclear medicine and molecular imaging. 2009;36(12):1968-76.
140